|
|
Volumn 85, Issue 1, 2001, Pages 33-42
|
|
Effect of vanadium(IV) compounds in the treatment of diabetes: In vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV)
a
|
|
Author keywords
Bis(maltolato)oxovandium(IV); BMOV; Diabetes; EPR; Vanadyl sulfate
|
|
Indexed keywords
APOTRANSFERRIN;
BIS(MALTOLATO)OXOVANDIUM;
HUMAN SERUM ALBUMIN;
IMMUNOGLOBULIN G;
PLASMA PROTEIN;
UNCLASSIFIED DRUG;
VANADIUM DERIVATIVE;
VANADYL SULFATE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
ATOMIC ABSORPTION SPECTROMETRY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG PROTEIN BINDING;
ELECTRON SPIN RESONANCE;
GLUCOSE BLOOD LEVEL;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
INSULIN SENSITIVITY;
MALE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
RAT;
SINGLE BLIND PROCEDURE;
STREPTOZOCIN DIABETES;
ANIMALS;
APOPROTEINS;
BIOLOGICAL AVAILABILITY;
BLOOD GLUCOSE;
DIABETES MELLITUS, EXPERIMENTAL;
DIABETES MELLITUS, TYPE 2;
ELECTRON SPIN RESONANCE SPECTROSCOPY;
FASTING;
HUMANS;
HYPOGLYCEMIC AGENTS;
IMMUNOGLOBULIN G;
MALE;
PYRONES;
RATS;
RATS, WISTAR;
SERUM ALBUMIN;
STREPTOZOCIN;
TRANSFERRIN;
TREATMENT OUTCOME;
VANADATES;
VANADIUM;
VANADIUM COMPOUNDS;
ANIMALIA;
RODENTIA;
SUS SCROFA;
|
|
EID: 0034983231
PISSN: 01620134
EISSN: None
Source Type: Journal
DOI: 10.1016/S0162-0134(00)00226-9 Document Type: Article |
|
Times cited : (207)
|
|
References (32)
|
